Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

August 30, 2023

Study Completion Date

December 30, 2028

Conditions
Neuroblastoma
Interventions
DRUG

Arsenic Trioxide

Arsenic trioxide(ATO) is administered 0.16mg/kg per day over eight hours IV daily for ten days. Patients will receive ATO alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Nine cycles at most of ATO-combined chemotherapy were applied in the whole scheme.

Trial Locations (1)

510120

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Yang Li

OTHER